5.00
0.01 (0.20%)
| Penutupan Terdahulu | 4.99 |
| Jumlah Dagangan | 251,290 |
| Harga / Jualan (P/S) | 15.56 |
| Harga / Buku (P/B) | 2.68 |
| Julat 52 Minggu |
| Margin Keuntungan | -229.11% |
| Margin Operasi (TTM) | -453.64% |
| EPS Cair (TTM) | -0.590 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.22% |
| Nisbah Semasa (MRQ) | 4.70 |
| Aliran Tunai Operasi (OCF TTM) | -38.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.82 M |
| Pulangan Atas Aset (ROA TTM) | -13.18% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | OmniAb, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.17 |
|
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.12% |
| % Dimiliki oleh Institusi | 67.98% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |